文献速递中医内科中药与中成药合理使用

天芪平颤颗粒治疗帕金森病左旋多巴诱导异动症的随机双盲安慰剂对照试验

Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial.
PubMed 文献 · J Integr Med · 2024-07-09

BACKGROUND: Patients with Parkinson's disease (PD) undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia (LID). Amantadine is the main drug recommended for the treatment of LID by current guidelines, but it is far from meeting clinical needs.…

要点

  • TPG联合金刚烷胺治疗12周可显著降低LID患者UDysRS评分。
  • 两组不良事件发生率均为4.0%,提示联合治疗耐受性良好。

核心结论

  • TPG联合金刚烷胺治疗12周可有效降低帕金森病伴LID患者的UDysRS评分,且耐受性良好。

研究设计与样本

  • 随机双盲安慰剂对照试验,于2020年1月至2021年8月在中国江苏、浙江和上海6个中心开展。

主要发现

  • 两组不良事件发生率均为4.0%(每组50例中2例)。

关键数值与推荐

  • 主要结局为统一异动症评定量表(UDysRS)评分(范围0-104)。
  • 关键次要终点为运动和非运动症状的改善。

临床怎么用

  • 对于长期使用左旋多巴并出现LID的帕金森病患者,可考虑在金刚烷胺基础上联用TPG以减轻异动症严重程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with Parkinson's disease (PD) undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia (LID). Amantadine is the main drug recommended for the treatment of LID by current guidelines, but it is far from meeting clinical needs. Tianqi Pingchan Granule (TPG), a compound Chinese herbal medicine, has been developed to relieve symptom of LID. OBJECTIVE: This randomized controlled trial evaluated the efficacy and safety of the combination of TPG and amantadine for LID. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a randomized double-blind placebo-controlled trial, conducted from January 2020 to August 2021 at 6 sites in Jiangsu, Zhejiang and Shanghai, China. One hundred PD patients with ≥ 0.5 h of LID were randomly assigned to either the TPG plus amantadine group (TPG group) or the placebo plus amantadine group (placebo group), and treated for a period of 12 weeks. To ensure unbiased results, all study participants, investigators and sponsors were unaware of group allocations. Additionally, the data analysts remained blinded until the analysis was finalized. MAIN OUTCOME MEASURES: The primary outcome was assessed using the Unified Dyskinesia Rating Scale (UDysRS) (Range 0-104). The key secondary end point was improvement of motor and non-motor symptoms. Safety analyses included all enrolled patients. RESULTS: One hundred patients were enrolled and randomized into the two treatment groups. The changes in UDysRS at week 12 were -11.02 for the TPG group and -4.19 for the placebo group (treatment difference -6.83 [-10.53 to -3.12]; P = 0.0004). Adverse events were reported for 2 of 50 patients (4.0%) in each of the groups. CONCLUSION: This study indicated that a 12-week treatment of amantadine plus TPG effectively reduced UDysRS scores and was well tolerated, demonstrating the efficacy and safety of TPG for the treatment of LID in PD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04173832. PLEASE CITE THIS ARTICLE AS: Zhang Y, Zhu XB, Zhao Y, Cui GY, Li WT, Yuan CX, Huang JP, Wan Y, Wu N, Song L, Zhao JH, Liang Y, Xu CY, Liu MJ, Gao C, Chen XX, Liu ZG. Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial. J Integr Med. 2024; 22(5): 545-551.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhu XB, Zhao Y, et al. Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial. J Integr Med. 2024. PMID: 39060125. doi:10.1016/j.joim.2024.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。